Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
01 October 2021 | Story Lunga Luthuli and Vicky Simpson | Photo Supplied
Anton Engelbrecht _ Farmovs researcher
Anton Engelbrecht, FARMOVS Bioanalysis Specialist.

“At FARMOVS, we have the opportunity to work with the world’s top pharmaceutical companies, where we form part of the evaluation of labelled and/or conjugated antigens and antibodies that are developed for accurate quantification of endogenous and pharmaceutical compounds. Alternatively, commercially available kits and reagents are also used for the same purpose if the sponsor cannot supply the customised antigens/antibodies. The developed assay methods are put through a rigorous validation assessment to confirm the selectivity, sensitivity, and robustness of the assay,” says Anton Engelbrecht, FARMOVS Bioanalysis Specialist. 

FARMOVS, affiliated to the University of the Free State and operating from the Bloemfontein Campus, is a leading clinical research organisation (CRO) with a unique advantage. As the only on-site ISO15189-accredited and GLP-certified pharmacokinetic laboratory on the African continent, with numerous successful inspections by leading international regulators, it offers the highest quality bioanalytical services in a variety of biological matrices for the development of pharmaceutical products.

Engelbrecht says: “The team of bioanalytical experts thrives on the excitement generated by new discoveries that lead to better treatment of a variety of physiological diseases.”

Advanced technology backed by 47 years of bioanalytical experience

The clinical research organisation prides itself on advanced technology, backed by 47 years of bioanalytical experience. It has developed more than 580 validated analytical methods that adhere to the International Council for Harmonisation and the US Food and Drug Administration (FDA) guidelines. FARMOVS’ analytical methods have been used in more than 3 000 pre-clinical and clinical trials, contributing to the manufacturing of pharmaceutical drugs that are now used by households across the globe.

At FARMOVS, Engelbrecht says, it is a “world filled with novel methods of analysis and subsequent technological integration that expands the horizons of clinical research forming an important part of the discovery and production of new life-saving medicines that is constantly improving the quality of life of people all over the world”.

Engelbrecht says: “New technology and innovation should be the building blocks of any laboratory, and among these are the three fastest sample production members of our Immunochemistry Laboratory team – the STARLet pipettors.”

“We chose the Microlab® STARLet apparatus by Hamilton, because of its ability to perform sample analysis in large quantities at a greater speed by means of robotic pipetting and robotic automated microplate reading, which is a semi-automated process.”

He shared his excitement about improvements in the field of immunoassay development for the purposes of pharmaceutical analysis. This involves the preparation of unique immunoanalytical reagents, analysis of new categories of compounds, methodology, and instrumentation. The most important examples in this field are the continuous development of bead-based immunoassays.

Staying competitive in the industry

Immunoassay methods, such as radioimmunoassay (RIA) and enzyme immunoassay (EIA), among others, are also used at FARMOVS to analyse macromolecules for clients. “The RIA method is used for the determination of several pharmaceutically important compounds in biological fluids. RIA requires a sample containing the antigen of interest, a complementary antibody, and a radiolabelled version of the antigen. To increase the selectivity of an assay, all samples are pre-treated to eliminate high molecular weight endogenous matrix components, including anti-drug antibodies,” explains Engelbrecht.

Although FARMOVS has adequate technology to provide market-related results, the plan is to expand the team to include a multiplex platform that is a sensitive, fully automated immunoassay platform with multiplexing and custom assay capability. “This will pave the way to use an even more sensitive method to quantify biomarkers in the fields of oncology, neurology, cardiology, inflammation, and infectious disease. We aim to remain competitive in our industry, so naturally we must recruit the brightest and most evolved to join the team,” he says.

News Archive

UFS research could light up South African homes
2016-01-21

Reitumetse Maloa, postgraduate student and researcher at the UFS Department of Microbial, Biochemical and Food Biotechnology, is using her research to provide solutions to the energy crises in South Africa.

A young researcher at the university is searching for the solution to South Africa’s energy and electricity problems from a rather unlikely source: cow dung.

“Cow dung could help us power South Africa,” explains Reitumetse Maloa, postgraduate student and researcher at the UFS Department of Microbial, Biochemical and Food Biotechnology.

Reitumetse’s research is trying to understand how the bacteria works that is responsible for producing biogas.

“Biogas can be used for cooking, heating, lighting and powering generators and turbines to make electricity. The remaining liquid effluent can fertilise crops, as it is high in nitrogen, phosphorus and potassium.”

By using cow dung and food waste to produce biogas, we will be able to lower greenhouse gases.

Biogas is produced in a digester - an oxygen-free space in which bacteria break down or digest organic material fed into the system. This process naturally produces biogas, which is mainly a mixture of methane and carbon dioxide.

“Many countries, such as Germany and the United States, have begun generating electricity from cow dung and food waste, through a process known as biogas production. In South Africa, a number of industries, including waste-water treatment facilities and farms, have caught on to this technology, using it to generate heat and to power machines.”

Until recently the world has relied heavily on electricity derived from fossil fuels such as coal, natural gas and oil. Once these fuels have been extracted from underground reservoirs, they are treated or cleaned, transported to power plants and transformed into the electricity that will reach your house. Fossil fuels are considered a ‘dirty’ energy source which gives off greenhouse gases when burned. Those gases are the major contributing factor to climate change.

“We know very little about the interaction of the bacteria inside the biogas digester. To use biogas as a sustainable fuel source, we need to understand and describe the bacteria population and growth dynamics inside the digester to produce biogas optimally. Currently we are testing a variety of feedstock, including bran, maize and molasses, for biogas production potential, as well as optimising the conditions leading to maximum biogas production. We are also exploring the potential to use the effluent as fertiliser on local farms. The ultimate goal is to have biogas systems that will supply our university with clean energy.”


We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept